PL2020996T3 - Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego - Google Patents
Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczegoInfo
- Publication number
- PL2020996T3 PL2020996T3 PL07794933T PL07794933T PL2020996T3 PL 2020996 T3 PL2020996 T3 PL 2020996T3 PL 07794933 T PL07794933 T PL 07794933T PL 07794933 T PL07794933 T PL 07794933T PL 2020996 T3 PL2020996 T3 PL 2020996T3
- Authority
- PL
- Poland
- Prior art keywords
- hematological malignancies
- compositions
- treating hematological
- compound
- salt
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 organic acid salt Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Processing Of Solid Wastes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80098306P | 2006-05-16 | 2006-05-16 | |
| US83180506P | 2006-07-18 | 2006-07-18 | |
| PCT/US2007/011726 WO2007136650A2 (en) | 2006-05-16 | 2007-05-16 | Method and compositions for treating hematological malignancies |
| EP07794933A EP2020996B1 (en) | 2006-05-16 | 2007-05-16 | Method and compositions for treating hematological malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2020996T3 true PL2020996T3 (pl) | 2012-04-30 |
Family
ID=38578698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07794933T PL2020996T3 (pl) | 2006-05-16 | 2007-05-16 | Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090258840A1 (pl) |
| EP (1) | EP2020996B1 (pl) |
| JP (2) | JP5544165B2 (pl) |
| KR (1) | KR101424832B1 (pl) |
| CN (1) | CN101442994B (pl) |
| AT (1) | ATE534377T1 (pl) |
| AU (1) | AU2007254309B2 (pl) |
| BR (1) | BRPI0711646C1 (pl) |
| CA (1) | CA2652048C (pl) |
| CY (1) | CY1112377T1 (pl) |
| DK (1) | DK2020996T3 (pl) |
| EA (1) | EA016995B1 (pl) |
| ES (1) | ES2377467T3 (pl) |
| MX (1) | MX2008014665A (pl) |
| NZ (1) | NZ572368A (pl) |
| PL (1) | PL2020996T3 (pl) |
| PT (1) | PT2020996E (pl) |
| SI (1) | SI2020996T1 (pl) |
| WO (1) | WO2007136650A2 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
| PL2020996T3 (pl) * | 2006-05-16 | 2012-04-30 | Gilead Sciences Inc | Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| EP3808752A4 (en) * | 2018-06-12 | 2022-03-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | 华南理工大学 | 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
| AU2002250058B2 (en) * | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| AU2002341327A1 (en) * | 2001-11-29 | 2003-06-10 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| GEP20063872B (en) * | 2001-12-12 | 2006-07-10 | Pfizer Prod Inc | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production |
| US7214668B2 (en) * | 2002-05-13 | 2007-05-08 | Metabasis Therapeutics, Inc. | Phosphonic acid based prodrugs of PMEA and its analogues |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| NZ575575A (en) * | 2003-08-18 | 2010-04-30 | Lundbeck & Co As H | Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| HRP20060254A2 (en) * | 2003-12-30 | 2006-10-31 | Gilead Sciences | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
| ATE445404T1 (de) | 2004-01-21 | 2009-10-15 | Gilead Sciences Inc | Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose |
| DE102005041860A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
| EP1965804A2 (en) * | 2005-12-16 | 2008-09-10 | Wyeth Pharmaceuticals | Lyophilized compositions of a triazolopyrimidine compound |
| PL2020996T3 (pl) * | 2006-05-16 | 2012-04-30 | Gilead Sciences Inc | Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego |
-
2007
- 2007-05-16 PL PL07794933T patent/PL2020996T3/pl unknown
- 2007-05-16 KR KR1020087030561A patent/KR101424832B1/ko active Active
- 2007-05-16 AU AU2007254309A patent/AU2007254309B2/en active Active
- 2007-05-16 PT PT07794933T patent/PT2020996E/pt unknown
- 2007-05-16 EA EA200802333A patent/EA016995B1/ru unknown
- 2007-05-16 MX MX2008014665A patent/MX2008014665A/es active IP Right Grant
- 2007-05-16 EP EP07794933A patent/EP2020996B1/en active Active
- 2007-05-16 WO PCT/US2007/011726 patent/WO2007136650A2/en not_active Ceased
- 2007-05-16 SI SI200730862T patent/SI2020996T1/sl unknown
- 2007-05-16 ES ES07794933T patent/ES2377467T3/es active Active
- 2007-05-16 DK DK07794933.7T patent/DK2020996T3/da active
- 2007-05-16 NZ NZ572368A patent/NZ572368A/en unknown
- 2007-05-16 JP JP2009511052A patent/JP5544165B2/ja active Active
- 2007-05-16 BR BRPI0711646A patent/BRPI0711646C1/pt active IP Right Grant
- 2007-05-16 CN CN200780017637XA patent/CN101442994B/zh active Active
- 2007-05-16 US US12/298,987 patent/US20090258840A1/en not_active Abandoned
- 2007-05-16 AT AT07794933T patent/ATE534377T1/de active
- 2007-05-16 US US11/803,822 patent/US20080039427A1/en not_active Abandoned
- 2007-05-16 CA CA2652048A patent/CA2652048C/en active Active
-
2011
- 2011-03-23 US US13/070,179 patent/US8435969B2/en active Active
-
2012
- 2012-02-16 CY CY20121100159T patent/CY1112377T1/el unknown
-
2013
- 2013-01-17 JP JP2013006055A patent/JP2013100324A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2020996T1 (sl) | Postopek in sestavki za zdravljenje hematološkihmalignosti | |
| MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
| SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
| TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| UA96777C2 (ru) | Фенилпропионамидные соединения и их применение как опиоидных агонистов | |
| MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| PL1737451T3 (pl) | Monocykliczne heterocykle jako inhibitory kinazy | |
| TN2009000034A1 (en) | Smac peptidomimetics useful as iap inhibitors | |
| TN2010000293A1 (en) | Thiazole derivatives used as pi 3 kinase inhibitors | |
| PH12013500913A1 (en) | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | |
| MX2009005934A (es) | Compuestos organicos. | |
| MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| CL2012000913A1 (es) | Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. | |
| NO20065416L (no) | Hemming av fremstillingen av biogene sulfider via kombinasjoner av biocide og metabolske inhibitorer | |
| MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
| MX2011007165A (es) | Derivados de piridazinona. | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| UA101018C2 (ru) | Пирролопиримидинкарбоксамиды | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| BRPI0821114A2 (pt) | Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer | |
| MX2009003102A (es) | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. | |
| MX2009009917A (es) | Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer. | |
| MX2011007232A (es) | Derivados de benzotiazolona. | |
| TW200718696A (en) | New derivatives of pyrrolyltriazine together with methods for obtaining them and their use as protecting agents against UV radiation |